CAMBRIDGE, Mass. (October 30th, 2018) – HotSpot Therapeutics, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance […]
“HotSpot is targeting natural regulatory sites on proteins that evolution has perfected over many millions of years. This allows us […]
Verge Scientific Communications 202.930.4762
HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T
HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets.
In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.
Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni
HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins.
In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.
With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence.
